Data on Anti-SARS-CoV-2 Antibodies (IgM/IgG) in COVID-19 Patients

Abstract

SARS-CoV-2 is an enveloped RNA virus capable of suffering mutations when passing from animals to humans, mutations which will allow for longer persistence in circulation but possibly also greater infectivity. If the disease is detected, the identification of viral RNA in pathological products harvested from the respiratory tract by molecular tests (RT-PCR) is the absolute recommendation. Serological tests have a role in estimating the extent of the population's immunization. Due to the high risk of infra-community transmission, it is essential to implement a surveillance program of all possible virus transmission routes. The purpose of the study was in line with the current epidemiological situation, to evaluate a molecular tool for improving the control of the spread of SARS-CoV-2, for risk assessment and for the development of a protocol for the epidemiological management of the COVID- 19 pandemic. An advantage is the access to a considerable number of cases - Bucharest ranked 1st place in the number of confirmed cases of COVID-19 on 30.09.2021.